title: Intraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from adjunctive and monotherapy treatments.
abstract: OBJECTIVE
  To evaluate efficacy, safety and quality of life in ocular hypertensive or open-angle glaucoma patients changed to latanoprost from previous therapy.
  
  
  METHODS
  A prospective, multicenter, active-controlled design in which qualified patients had their previous therapy substituted for latanoprost and were followed for at least three months.
  
  
  RESULTS
  In 1068 patients, latanoprost was continued 92% throughout the 36-month observation period. Latanoprost treatment reduced the intraocular pressure (1OP)(p < 0.001) when compared to previous monotherapies including: beta-blockers (-4.0 +/- 3.7 mmHg, 42%), alpha-antagonists (-3.9 +/- 3.0 mmHg, 14%), miotics (-3.8 +/- 3.5 mmHg, 2%), or carbonic anhydrase inhibitors (CAI) (-3.8 +/- 3.6 mmHg, n = 16%), and adjunctive therapy including: beta-blocker and CAI (-3.7 +/- 3.1 mmHg, n = 12%), alpha-agonist (-3.7 +/- 3.4 mmHg, n = 5%), or pilocarpine (-3.4 +/- 3.7 mmHg, n = 6%), or CAI and alpha-agonist (-4.6 +/- 6.4 mm Hg, n = 2%)(p < 0.0017). The most common adverse event with latanoprost was ocular allergy (1.5% incidence). Patients showed a preference for latanoprost for many systemic and ocular quality of life measures on a non-validated questionnaire (p < 0.05).
  
  
  CONCLUSIONS
  In a clinical setting, patients who have their mono- and adjunctive therapy treatment substituted for latanoprost may on average experience reduced IOP, decreased side effects and increased quality of life measures.
authors.affiliation: Children Hospital at the University of Bonn, Bonn.
authors.forename: F
authors.initials: F
authors.lastname: Haverkamp
authors.forename: S
authors.initials: S
authors.lastname: Wuensch
authors.forename: M
authors.initials: M
authors.lastname: Fuchs
authors.forename: W C
authors.initials: WC
authors.lastname: Stewart
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004359:Drug Therapy, Combination; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D011788:Quality of Life; D012449:Safety; D011795:Surveys and Questionnaires
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost